Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Times Interest Earned (2021 - 2025)

Historic Times Interest Earned for BioNexus Gene Lab (BGLC) over the last 5 years, with Q3 2025 value amounting to -$108.38.

  • BioNexus Gene Lab's Times Interest Earned rose 4982.23% to -$108.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$106.35, marking a year-over-year decrease of 13069.75%. This contributed to the annual value of -$74.42 for FY2024, which is 6003.19% up from last year.
  • Per BioNexus Gene Lab's latest filing, its Times Interest Earned stood at -$108.38 for Q3 2025, which was up 4982.23% from -$125.29 recorded in Q2 2025.
  • BioNexus Gene Lab's 5-year Times Interest Earned high stood at $89.48 for Q2 2023, and its period low was -$593.69 during Q3 2023.
  • Over the past 5 years, BioNexus Gene Lab's median Times Interest Earned value was -$33.7 (recorded in 2024), while the average stood at -$66.85.
  • The largest annual percentage gain for BioNexus Gene Lab's Times Interest Earned in the last 5 years was 25040.5% (2023), contrasted with its biggest fall of 198625.16% (2023).
  • BioNexus Gene Lab's Times Interest Earned (Quarter) stood at -$50.44 in 2021, then skyrocketed by 151.08% to $25.76 in 2022, then soared by 139.17% to $61.62 in 2023, then crashed by 216.22% to -$71.61 in 2024, then crashed by 51.34% to -$108.38 in 2025.
  • Its Times Interest Earned was -$108.38 in Q3 2025, compared to -$125.29 in Q2 2025 and -$125.98 in Q1 2025.